ALK and lung cancer: Some strategies have been proven effective in human trials, for example, the use of ceritinib, a new ALK (anaplastic lymphoma kinase gene) inhibitor, in patients with advanced lung cancers harboring genetic alterations in ALK, in a phase 1 study [15].